Downers Grove, IL – Coventry recently announced the release of the second part of its 2017 Drug Trends Series, which is based on all calendar year transactions billed through its PBM Program, First Script, as well as transactions from medical bill review to reflect the total pharmacy experience for their client base.
With this report Coventry is continuing to distribute its trends analyses in shorter, easier-to-digest installments rather than as a single voluminous document. Coventry based its decision on the supportive feedback many offered when they adopted this approach for reporting 2016 results a year ago.
This second piece in the series focuses on the “managed” and “unmanaged” views. The managed data takes the traditional view (retail + mail order) and adds prescriptions from Coventry’s extended network. The unmanaged data represents the out-of-network prescriptions that are received and processed through medical bill review.
Key trends from this piece included:
- Generic utilization continues to trend up, increasing by at least 1% pts for both prescription populations (managed 86.8%, unmanaged 81.8%).
- Opioid utilization continues to decrease in both groups, declining 1.2% pts for managed (28.9%) and 1.8% pts for unmanaged (10.8%).
- High-dollar, private-label topical analgesics marketed directly to physicians’ offices are contributing to a significant rise in unmanaged topical utilization per claim (up 9.8%), demonstrating the need for continued focus on moving the transactions into the PBM.
- Compound utilization has decreased in both groups, declining by 0.2% pts for managed (accounting for only 0.2% of scripts) and 2.8% pts for unmanaged (now accounting for only 1.3% of scripts).
View Part 2 here: Coventry 2017 First Script Drug Trends Report Series, Part 2 (PDF)
or Catch up on Part 1 here: Coventry 2017 First Script Drug Trends Report Series, Part 1 (PDF)
Coventry is a WorkCompWire ad partner.
This is not a paid placement.